Insulin therapy in type 2 diabetes mellitus

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 119-144

  Leahy, Jack L ^a  

^a University of Vermont Colchester Research Facility   (United States)

Author keywords

Glucose control; Insulin therapy; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; PIG INSULIN; PLACEBO; SHORT ACTING INSULIN; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; VILDAGLIPTIN;

BEDTIME DOSAGE; BOLUS INJECTION; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84860638308     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.03.004     Document Type: Review

References (150)

1. 2011 National Diabetes Fact Sheet. Available at:. Accessed January 28, 2012. http://www.cdc.gov/diabetes/pubs/factsheet11/htm.
2. IDF Diabetes Atlas 5th edition. Available at:. Accessed January 28, 2012. http://www.idf.org/diabetesatlas/5e/the-global-burden.
3. Leahy J.L., Pratley R.E. What is type 2 diabetes mellitus? Crucial role of maladaptive changes in beta cell and adipocyte biology. Translational Endocrinology and Metabolism 2011, 2:9-42.
4. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus: fasting blood glucose concentration and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors Collaboration.
5. Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus: fasting glucose and risk of cause-specific death. N Engl J Med 2011, 364:829-841. Emerging Risk Factors Collaboration.
6. Rosenbaum L., Lamas D. Facing a "slow-motion disaster" -the UN meeting on noncommunicable diseases. N Engl J Med 2011, 365:2345-2348.
7. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
8. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559. Available at:, Accessed January 28, 2012. https://www.aace.com/sites/default/files/GlycemicControl/Algorithm.pdf.
9. American Diabetes Association Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1):S11-S63.
10. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187-192.
11. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009, 373:1765-1772.
12. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
13. Zhang C.Y., Sun A.J., Zhang S.N., et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Ann Med 2010, 42:305-315.
14. Gæde P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
15. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
16. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
17. deBoer I.H., Sun W., Cleary P.A., et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011, 365:2366-2376.
18. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008, 6:54-67.
19. Polonsky W.H., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005, 28:2543-2545.
20. Cefalu W.T., Mathieu C., Davidson J., et al. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. Diabetes Technol Ther 2008, 10:25-38.
21. Polonsky W.H., Hajos T.R., Dain M.P., et al. Are patients with type 2 diabetes reluctant to start insulin? An explanation of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin 2011, 27:1169-1174.
22. Nakar S., Yitzhaki G., Rosenberg R., et al. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007, 4:220-226.
23. Jenkins N., Hallowell N., Farmer A.J., et al. Initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences. Diabetes Care 2010, 33:2178-2180.
24. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
25. Yki-Järvinen H., Kauppinen-Mäkelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006, 49:442-451.
26. Bretzel R.G., Nuber U., Landgraf W., et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. Lancet 2008, 371:1073-1084.
27. Turner R.C., McCarthy S.T., Holman R.R., et al. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976, 1:1252-1254.
28. Garvey W.T., Olefsky J.M., Griffin J., et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
29. Bunck M.C., Diamant M., Corner A., et al. One-year treatment with exenatide improves ß-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care 2009, 32:762-768.
30. Ilkova H., Glaser B., Tunckle A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin therapy. Diabetes Care 1997, 20:1351-1356.
31. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
32. Li Y., Xu W., Liao Z.H., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27:2597-2602.
33. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008, 371:1753-1760.
34. Hølberg P.V., Zander M., Visbøll T., et al. Near normalization of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008, 51:632-640.
35. Hølberg P.V., Visbøll T., Robøl R., et al. Four-weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207.
36. Riddle M.C. New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1985, 1:192-195.
37. Yki-Järvinen H., Kauppila M., Kajansuu E., et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:1426-1433.
38. Riddle M., Hart J., Bingham P., et al. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992, 303:151-156.
39. Alexander G.C., Sehgal N.L., Moloney R.M., et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008, 169(19):2088-2094.
40. Li C., Ford E.S., Zhao G., et al. Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995-2007. J Diabetes Complications 2012, 26(1):17-22.
41. UK Prospective Diabetes Study Group 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
42. Wright A., Burden A.C., Paisey R.C., et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
43. Riddle M.C., Rosenstock J., Gerich J., et al. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086.
44. Kennedy L., Herman W.H., Strange P., et al. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2008, 29:1-8.
45. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
46. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28:950-955.
47. Monami M., Marchiommi N., Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 81:184-189.
48. Home P.D., Fritsche A., Schinzel S., et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010, 12:772-779.
49. Rosenstock J., Davies M., Home P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008, 51:408-416.
50. Dailey G., Admane K., Mercier F., et al. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 2010, 12:1019-1027.
51. Lucidi P., Porcellati F., Rossetti P., et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 2011, 34:1312-1314.
52. Porcellati F., Lucidi P., Rossetti P., et al. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care 2011, 34:2521-2523.
53. King A.B. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. J Diabetes Sci Technol 2010, 4:151-154.
54. Birkeland K.I., Home P.D., Wendisch U., et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34:661-665.
55. Zinman B., Fulcher G., Rao P.V., et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomized, open label, phase 2 trial. Lancet 2011, 377:924-931.
56. Heise T., Tack C.J., Cuddihy R., et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011, 34:699-774.
57. Little S., Shaw J., Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011, 13(Suppl 1):S53-S64.
58. Giugliano D., Maiorino M.I., Bellastella G., et al. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2011, 92:1-10.
59. Riddle M.C., Vlajnic A., Zhou R., et al. Baseline A1c predicts the likelihood of reaching the 7.0% A1c target with structured titration of add-on insulin glargine: patient-level analysis of 12 studies in type 2 diabetes. Diabetes 2009, 58(Suppl 1):A125.
60. Leahy J., Vlajnic A., Rimler M., et al. Lower weight gain and better outcomes in patients with type 2 diabetes starting insulin treatment when baseline A1c <8%. Diabetologia 2011, 54(Suppl 10):S273.
61. Riddle M., Umpierrez G., Digenio A., et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011, 34:2508-2514.
62. Monnier L., Colette C., Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011, 12(Suppl 1):S25-S32.
63. O'Keefe J.H., Bell D.S. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100:899-904.
64. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28:254-259.
65. Janka H.U., Högy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2008, 9:165-170.
66. Tunis S.L., Sauriol L., Minshall M.E. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. Appl Health Econ Health Policy 2010, 8(4):267-280.
67. McNally P.G., Dean J.D., Morris A.D., et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared to biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007, 30:1044-1048.
68. Qayyum R., Bolen S., Maruther N., et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008, 149:549-559.
69. Heise T., Heinemann L., Hövelmann U., et al. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care 2009, 32:1431-1433.
70. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
71. Kann P.H., Wascher T., Zackova V., et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006, 114:527-532.
72. Buse J.B., Wolffenbuttel B.H., Herman W.H., et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009, 32:1007-1013.
73. Buse J.B., Wolffenbuttel B.H., Herman W.H., et al. The DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care 2011, 34:249-255.
74. Garber A.J., Wahlen T., Wahl T., et al. Attainment of glycaemic goals with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006, 8:58-66.
75. Robbins D.C., Beisswenger P.J., Ceriello A., et al. Mealtime 50/50 basal + prandial insulin analogue with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007, 29:2349-2364.
76. Clements M.R., Tits J., Kinsley B.T., et al. Improved glycaemic control of thrice-daily biphasic insulin aspart compared to twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008, 10:229-237.
77. Farcasiu E., Ivanyi T., Mozejko-Pastewka B., et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clin Ther 2011, 33:1682-1693.
78. Davies M., Sinnassamy P., Storms F., et al. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 2008, 79(2):368-375.
79. Schiel R., Müller U.A. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes 2008, 116:58-64.
80. Bretzel R.G., Eckhard M., Landgraf W., et al. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents. Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 2009, 32(Suppl 2):S260-S265.
81. Bergenstal R.M., Johnson M., Powers M.A., et al. Adjust to target in type 2 diabetes: comparison of a simple regimen with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008, 31:1305-1310.
82. Hollander P., Cooper J., Bregnhøj J., et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008, 30:1976-1987.
83. Raskin P., Gylvin T., Weng W., et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009, 25:542-548.
84. Siegmund T., Weber S., Blankenfeld H., et al. Comparison of insulin glargine versus NPH insulin in people with type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007, 115:349-353.
85. Liebl A., Prager R., Binz K., et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009, 11:45-52.
86. Fritsche A., Larbig M., Owens D., et al. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010, 12:115-123.
87. Rosenstock J., Ahmann A.J., Colon G., et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-25.
88. Raccah D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab 2008, 10(Suppl 2):76-82.
89. Lankisch M.R., Ferlinz K.C., Leahy J.L., et al. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185.
90. Owens D.R., Luzio S.D., Sert-Langeron C., et al. Effects of initiation of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month "proof-of-concept". Diabetes Obes Metab 2011, 13:1020-1027.
91. Del Prato S., Nicolucci A., Lovagnini-Scher A.C., et al. Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther 2012, 14(2):175-182.
92. Riddle M.C., Vlajnic A., Jones B.A., et al. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine. Diabetes 2011, 60(Suppl 1):A113.
93. Rosenstock J., Vlajnic A., Jones B.A., et al. Time course of fasting glucose, hypoglycemia and body weight during systematic insulin dose titration: BID aspart premixed vs glargine +1 prandial glulisine or stepwise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents. Diabetes 2011, 60(Suppl 1):A20.
94. Holman R.R., Thorne K.I., Farmer A.J., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
95. Holman R.R., Farmer A.J., Davies M.J., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-1747.
96. Bode B.W. Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010, 12(Suppl 1):S17-S21.
97. Bulchandani D.G., Konrady T., Hamburg M.S. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract 2007, 13:721-725.
98. Edelman S.V., Bode B.W., Bailey T.S., et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther 2010, 12:627-633.
99. Reznik Y., Morera J., Rod A., et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol Ther 2010, 12:931-936.
100. Frias J.P., Bode B.W., Bailey T.S., et al. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol 2011, 5:887-893.
101. Raskin P., Bode B.W., Marks J.B., et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003, 26:2598-2603.
102. Monami M., Lamanna C., Marchionni N., et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes 2009, 117:220-222.
103. Skladany M.J., Miller M., Guthermann J.S., et al. Patch-pump technology to manage type 2 diabetes mellitus: hurdles to market acceptance. J Diabetes Sci Technol 2008, 2:1147-1150.
104. Anhalt H., Bohannon N.J. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010, 12(Suppl 1):S51-S58.
105. Dorkhan M., Frid A., Groop L. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add-insulin glargine or pioglitazone?. Diabetes Res Clin Pract 2008, 82:340-345.
106. Rosenstock J., Sugimoto D., Strange P., et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 2006, 29:554-559.
107. Triplitt C., Glass L., Miyazaki Y., et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006, 29:2371-2377.
108. Hohberg C., Pfützner A., Forst T., et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab 2009, 11:464-471.
109. Bell D.S., Dharmalingam M., Kumar S., et al. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab 2011, 13:800-805.
110. Lingvay I., Legendre J.L., Kaloyanova P.F., et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?. Diabetes Care 2009, 32:1789-1795.
111. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
112. Garber A.J. Long-acting glucagon-like peptide 1 receptor agonists. A review of the efficacy and tolerability. Diabetes Care 2011, 34(Suppl 2):S279-S284.
113. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
114. Bergenstal R., Leewin A., Bailey T., et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009, 25:65-75.
115. Gallwitz B., Böhmer M., Segiet T., et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011, 34:604-606.
116. Thong K.Y., Ryder R.E., Cull M.L., et al. Insulin avoidance and treatment outcomes among patients with a professional driving license starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabet Med 2012, 29:690-692.
117. Davis S.N., Johns D., Maggs D., et al. Exploring the substitution of exenatide for insulin with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007, 30:2767-2772.
118. Rosenstock J., Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!. Diabetes Care 2007, 30:2972-2973.
119. Morrow L., Hompesch M., Guthrie H., et al. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011, 13:75-80.
120. Viswanathan P., Chaudhuri A., Bhatia R., et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007, 13:444-450.
121. John L.E., Kane M.P., Busch R.S., et al. Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 2007, 20:59-63.
122. Sheffield C.A., Kane M.P., Busch R.S., et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes. Endocr Pract 2008, 14:285-292.
123. Yoon N.M., Cavaghan M.K., Brunelle R.L., et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009, 31:1511-1523.
124. Lane W., Weinrib S., Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011, 13:592-595.
125. Arnolds S., Dellweg S., Clair J., et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.
126. Buse J.B., Bergenstal R.M., Glass L.C., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
127. Rosenstock J., Devries J.H., Seufert J., et al. A new type 2 diabetes treatment paradigm: sequential addition of liraglutide to metformin and then basal insulin detemir. Diabetes 2011, 60(Suppl 1):A76.
128. Kielgast U., Krarup T., Holst J.J., et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 334:1463-1468.
129. Varanasi A., Bellini N., Rawal D., et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011, 165:77-84.
130. Fonseca V., Schweizer A., Albrecht D., et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
131. Visbøll T., Rosenstock J., Yki-Järvinen H., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
132. Sasali A., Leahy J.L. Insulin therapy for type 2 diabetes. Curr Diab Rep 2003, 3:378-385.
133. Yki-Järvinen Y. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001, 24:758-767.
134. Riddle M.C. Combined therapy with insulin plus oral agents: is there any advantage?. Diabetes Care 2008, 31(Suppl 2):S125-S130.
135. Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev 2008, 24:3-13.
136. Riddle M., Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21:1052-1057.
137. Yki-Järvinen Y., Ryysy L., Nikkila K., et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
138. Fonseca V., Gill J., Zhou R., et al. An analysis of early insulin glarine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011, 13:814-822.
139. Swinnen S.G., Dain M.P., Mauricio D., et al. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab 2010, 12:923-925.
140. Smith U., Gale A.M. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009, 52:1699-1708.
141. Currie C.J., Johnson J.A. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012, 14:1-4.
142. Origin Trial Investigators, Gerstein H., Yusuf S., et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN trial (Outcome reduction with an Initial Glargine Intervention). Am Heart J 2008, 155:26-32.
143. Diamant M., Van Gaal L., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
144. Diamant M., Van Gaal L., Stranks S., et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012, 35:683-689.
145. Funnell M.M., Brown T.L., Childs B.P., et al. National standards for diabetes self-management education. Diabetes Care 2011, 34(Suppl 1):S89-S96.
146. Cochran J., Conn V.S. Meta-analysis of quality of life outcomes following diabetes self-management training. Diabetes Educ 2008, 34:815-823.
147. Poolsup N., Suksomboon N., Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technol Ther 2009, 11:775-784.
148. Clar C., Barnard K., Cummins E., et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010, 14:1-140.
149. Gerstein H.C., Yale J.F., Harris S.B., et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006, 23:736-742.
150. O'Rahilly S., Weir G.C., Matthews D.R. An appreciation of Robert Turner. Diabetes 2008, 57:2819-2821.